|
FDA to Describe Strategies for Handling Multiplicity in Upcoming Multiple Endpoints Guidance
PHILADELPHIA — Trial sponsors can minimize multiplicity concerns that arise from conducting studies with multiple endpoints by employing an “Occam’s razor-like philosophy,” an FDA official recommends.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives